Improving the Patient Experience with High Viscosity/High Volume Drugs
On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.
On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience.
As biologics with high viscosity and/or high volume are becoming more prominent in the development landscape, particularly for chronic diseases, it is becoming more pertinent to assess the administration methods for these therapies. Often, subcutaneous administration of high viscosity or high-volume drugs can be painful and ultimately lead to lower patient adherence.
To overcome the challenges associated with high viscosity/high-volume therapies and improve overall patient experience, it may be necessary to employ shorter needles and autoinjector solutions. Using the BD Intevia platform as an example, Yadi will discuss the engineering process required to successfully integrate combination products into one performing system.
High Viscosity/High Volume Drugs-Challenges and Needs for Shorter Needles and Integrated SystemsTuesday Nov. 5, 2019 15:10–15:40 InnoPack & P-MEC Theatre (110D50)
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
